NDT Advance Access originally published online on January 23, 2006
Nephrology Dialysis Transplantation 2006 21(6):1640-1647; doi:10.1093/ndt/gfk088
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Original Articles: Dialysis and Transplantation
Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients
1 Cardiovascular Division, 2 Division of Urology and 3 Division of Surgery, Toujinkai Hospital, Kyoto, 4 Department of Interventional Cardiology, Kyoto Second Red Cross Hospital, Kyoto and 5 Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi, Japan
Correspondence and offprint requests to: Masato Nishimura, MD, Cardiovascular Division, Toujinkai Hospital, 83-1, Iga, Momoyama-cho, Fushimi-ku, Kyoto 612-8026, Japan. Email: mnishimura{at}tea.ocn.ne.jp
Background. Success of coronary stenting is limited by in-stent restenosis. We aimed to determine whether circulating levels of the cytokines, which have anti-inflammatory properties such as adiponectin or interleukin-10, could be associated with the occurrence of coronary in-stent restenosis in patients with end-stage renal disease (ESRD).
Methods. We enrolled 71 consecutive ESRD patients undergoing haemodialysis (mean age: 64.9±8.9 years; 19 women, 52 men; mean haemodialysis duration: 78.2±87.5 months), who received stenting for a single coronary lesion. Plasma concentrations of adiponectin and IL-10 were measured within one week before coronary stenting.
Results. Of the 71 patients who had received stenting, in-stent restenosis occurred in 37 patients (52.1%) within 6 months after stenting. In univariate logistic analysis, the homeostasis model assessment index of insulin resistance, blood haemoglobin, serum concentrations of high density lipoprotein–cholesterol or triglycerides and plasma concentrations of insulin or adiponectin were significantly associated with coronary in-stent restenosis. In a multiple logistic regression analysis among these variables, however, only the plasma adiponectin concentration was associated with the coronary in-stent restenosis: the odds ratio of the increase in 1 µg/ml of plasma adiponectin concentration for having restenosis was 0.651 (P = 0.001, 95% confidence interval: 0.506–0.839). Patients with restenosis had lower plasma adiponectin concentrations than those without [6.2±2.2 µg/ml (2.1–10.4 µg/ml; n = 37) vs 27.2±10.8 µg/ml (17.9–79.8 µg/ml; n = 34); P = 0.0001].
Conclusions. Circulating adiponectin concentrations may be associated with the occurrence of coronary in-stent restenosis in ESRD patients undergoing maintenance haemodialysis.
Keywords: adiponectin; coronary artery disease; haemodialysis; restenosis; stenting
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bacchetta, S. Boutroy, F. Guebre-Egziabher, L. Juillard, J. Drai, S. Pelletier, M. Richard, A. Charrie, M. C. Carlier, R. Chapurlat, et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease Nephrol. Dial. Transplant., June 10, 2009; (2009) gfp262v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|